Alpine Immune Sciences (Alpine Immune Sciences) Net Margin % : 19.32% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Alpine Immune Sciences Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Alpine Immune Sciences's Net Income for the three months ended in Dec. 2023 was $5.96 Mil. Alpine Immune Sciences's Revenue for the three months ended in Dec. 2023 was $30.85 Mil. Therefore, Alpine Immune Sciences's net margin for the quarter that ended in Dec. 2023 was 19.32%.

The historical rank and industry rank for Alpine Immune Sciences's Net Margin % or its related term are showing as below:

ALPN' s Net Margin % Range Over the Past 10 Years
Min: -5175.46 Med: -299.3 Max: -54.66
Current: -54.66

ALPN's Net Margin % is ranked better than
61.05% of 1027 companies
in the Biotechnology industry
Industry Median: -160.92 vs ALPN: -54.66

Alpine Immune Sciences Net Margin % Historical Data

The historical data trend for Alpine Immune Sciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Net Margin % Chart

Alpine Immune Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-2,405.29

-299.30

-214.70

-192.13

-54.66

Alpine Immune Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-679.54	-141.32	-153.10	-116.72	19.32

Competitive Comparison of Alpine Immune Sciences's Net Margin %

For the Biotechnology subindustry, Alpine Immune Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpine Immune Sciences's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's Net Margin % falls into.

Alpine Immune Sciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Alpine Immune Sciences's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-32.184	/	58.876
	=	-54.66 %

Alpine Immune Sciences's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	5.96	/	30.853
	=	19.32 %

Alpine Immune Sciences (NAS:ALPN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Alpine Immune Sciences Net Margin % Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Immune Sciences (Alpine Immune Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (NAS:ALPN) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

34LA:Germany

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Executives

Mitchell Gold	director, officer: Executive Chairman and CEO	ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James Paul Rickey	officer: Senior VP and CFO	ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102
Xiangmin Cui	director, 10 percent owner	NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Wolfgang Dummer	officer: Chief Medical Officer	5491 OPTICAL CT., SAN JOSE CA 95138
Remy Durand	officer: Chief Business Officer	C/O ALPINE IMMUNE SCIENCES, INC., 185 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98012
Jorn Drappa	director	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Andrew Seth Sandler	officer: Chief Medical Officer	1301 2ND AVE, SEATTLE WA 98101
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert E Conway	director	C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
Christopher Peetz	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Decheng Capital China Life Sciences Usd Fund Iii, L.p.	10 percent owner	UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
Alpine Immunosciences, L.p.	10 percent owner	600 STEWART STREET, SUITE 1503, SEATTLE WA 98101
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022